Michael Scholle, MS, MBA

Michael Scholle, MBA, is the CEO and co-founder of Tango Biosciences, a CRO offering affinity reagent and peptide drug discovery solutions.

Scholle brings over 25 years of experience commercializing technology platforms, high-throughput drug discovery, MALDI TOF mass spectrometry, biochemistry, molecular biology, antibody and peptide discovery. From developing novel assays using innovative surface chemistries and integrating automated solutions, Scholle brings in-depth experience in CRO executive leadership, operations, and building biotech companies.

Prior to Tango Biosciences, Scholle was Site head and Operations Director at Charles River Chicago after their acquisition of SAMDI Tech, Inc. where Scholle was Chief Operating Officer and a Co-Founder. Scholle was a staff scientist at Integrated Genomics, Inc., Argonne National Laboratory, and a founding scientist at Amunix, Inc (acquired by Sanofi). Throughout his career, he has authored numerous peer-reviewed articles published in scientific and business journals. Scholle earned a master’s degree in biology from Northern Illinois University and an MBA from Roosevelt University Chicago.